Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Rivaroxaban Under Review for Risk of Interstitial Pneumonia: PMDA
January 29, 2014
- PAFSC’s Second Committee to Review Taiho’s Novel Anticancer Agent on Feb. 3
January 28, 2014
- MHLW Setting Out on Development of iPS Tech-Based Cardiotoxicity Evaluation
January 28, 2014
- PAFSC’s First Committee Supports Approval of Second SGLT-2 Inhibitor Dapagliflozin
January 27, 2014
- FDA Bans Imports from Ranbaxy’s Toansa Plant, Daiichi Sankyo Promises Full Cooperation with FDA
January 27, 2014
- Health Minister Waits for Investigation Results on Novartis Involvement in “Sign” Study
January 27, 2014
- Comprehensive Strategy Proposal for “Japan NIH” Calls for Study on Legislation to Prevent Clinical Research Fraud by Autumn
January 27, 2014
- Expert Groups Call for Early Resumption of Active Recommendation for HPV Vaccines
January 27, 2014
- Regulatory Reform Council Eyes New Special System for Mixed Healthcare
January 24, 2014
- NHI Pricing of Generics Set to Undergo Major Revision to Help MHLW Achieve New Target; Promotion through Medical Fee Revision Also Planned
January 24, 2014
- DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision
January 23, 2014
- Chuikyo OKs New NHI Drug Pricing Rules for FY2014 Revision
January 23, 2014
- Gov’t to Fully Implement Japan Version of “Compassionate Use” System in FY2015
January 23, 2014
- Final Decision on Active Recommendation for HPV Vaccines Will Be Made at Next Subcommittee Meeting: Minister
January 23, 2014
- Revised PAL to Ensure Drug Safety to Take Effect in Late November
January 22, 2014
- Novartis Sales Rep Involvement in Investigator-Initiated Trial “Extremely Regrettable”: Health Minister Tamura
January 22, 2014
- No Hand Raised for Additional Applicant Appeal for New Flu Vaccine Project, Quota for 25 Million People in Limbo
January 21, 2014
- HPV Vaccine Injection Site Pain Possible Cause of Chronic Pain: MHLW Subcommittees
January 21, 2014
- Prescribing of Torii’s Sublingual Cedar Pollinosis Treatment Cedartolen to be Restricted to Trained Doctors
January 21, 2014
- MHLW Approves Japan’s 1st SGLT-2 Inhibitor, Boehringer’s Anticancer Drug
January 20, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…